Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Tobii AB (publ) in connection with its rights issue
Mandate

Vinge has advised Tobii AB (publ) in connection with its rights issue

April 03, 2024 Capital Markets and Public M&A

Vinge has advised Tobii AB (publ) in connection with a fully guaranteed rights issue of ordinary shares which will provide Tobii with issue proceeds of approximately SEK 301 million before deduction of transaction costs.

The new ordinary shares issued in the rights issue are expected to be admitted to trading on Nasdaq Stockholm on or around 15 April 2024. Tobii develops technology within eye tracking and attention computing which understands human attention and intent. Tobii’s eye tracking solutions are used by thousands of enterprises, universities and research institutes around the globe. The company's ordinary shares are listed on Nasdaq Stockholm.

 

Vinge’s team consisted primarily of Jesper Schönbeck, Rikard Lindahl, Amanda Knutsson, Joel Magnusson, Oskar Nilsson, Lorin Arabi, Elias Kröger, Lovisa Jonassen och William Carlberg Johansson.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025